AMENDMENTS TO THE CLAIMS

1. (Currently amended) A compound of the formula:

[Formula 1]

(wherein:

R¹ is optionally substituted aralkyl substituted with halogen;

R² is hydrogen or lower alkyl;

R³ is optionally substituted alkyl (substituent: lower alkoxy, amino optionally substituted with lower alkyl, cyano, hydroxy, carboxy, or lower alkoxycarbonyl) or optionally substituted amino (provided that each substituent for "optionally substituted" is a noneyelic group) (substituent: lower alkyl);

R⁴ is hydrogen, optionally substituted carboxy (substituent: lower alkyl, hydroxy lower alkyl, lower alkyl, optionally substituted amino lower alkyl, or an optionally substituted heterocyclic group), optionally substituted formylamino (substituent: lower alkyl, hydroxy lower alkyl, lower alkoxy lower alkyl, optionally substituted carbamoyl lower alkyl, optionally substituted lower alkoxy, optionally substituted amino, or optionally substituted carbamoyl), optionally substituted carbamoyl (substituent: lower alkyl, optionally substituted lower alkyl (substituted amino, optionally substituted amino, optionally substituted lower alkoxy, carbamoyl), or optionally substituted heterocyclic group lower alkyl), optionally substituted amino (provided that a substituent on amino in "optionally substituted formylamino", "optionally substituted carbamoyl" and "optionally substituted amino" may form an optionally substituted N atom containing heterocyclic ring together with an adjacent N atom), optionally substituted alkyl (substituent: hydroxy, halogen, an optionally substituted heterocyclic group, optionally substituted lower alkoxy, optionally substituted alkenyl (substituent: hydroxy, halogen, an optionally substituted lower lower alkoxy, optionally substituted alkenyl (substituent: hydroxy, halogen, an optionally substituted lower low

alkoxy, optionally substituted amino, optionally substituted carbamoyl, or optionally substituted carboxy), or a pharmaceutically acceptable salt thereof (except for Compound (I-A) shown in Table 1 below)

[Table 1]

[Formula I-A]

F CONR²R³

$$R^4$$
(I-A)

Compound	\mathbb{R}^2	\mathbb{R}^3	\mathbb{R}^4
No.			
20	Н	CH2CH2OMe	Н
27	Н	Me	NHMs
28	Н	CH2CH2OMe	NHMs
29	Н	i-Pr	NHMs
85	Me	Me	Н
86	Н	NHMe	Н
87	Н	NMe2	Н
88	Н	OMe	Н
89	Н	Н	Н
90	Н	Me	Н
91	Н	Et	Н
92	Н	i-Pr	Н
126	Н	CH2CH2NMe2	Н
160	H	CH2CH2OMe	NHCOCH2OMe
161	Н	CH2CH2OMe	NHCOCH2CH2CO2Et
162	Н	CH2CH2OMe	NHCOCH2CO2Et
163	Н	CH2CH2OMe	NHCOOEt
164	Н	CH2CH2OMe	NHCOCH2CH2OMe
165	Н	CH2CH2OMe	NHCO-thiophene
180	Н	CH2CH2OMe	Ph-CH2OH
181	Н	NMe2	Ph-CH2OH

(Me=methyl; i-Pr=isopropyl; Et=ethyl; Ms=methanesulfonyl; thiophene=thiophene; Ph=phenyl).

- 2. (Previously presented) The compound according to claim 1, wherein R¹ is p-fluorobenzyl, or a pharmaceutically acceptable salt thereof.
- 3. (Cancelled)
- 4. (Previously presented) The compound according to claim 1, wherein R² is hydrogen; R³ is CH₂CH₂OCH₃, CH₂CH₂OEt, CH₂CH₂COOCH₃, CH₂CH₂CH₂OCH₃, CH₂CH₂CH₂O(i-Pr), N(CH₃)₂, CH₂CH₂CN, CH₂CH₂N(CH₃)₂, CH₂CH₂N(i-Pr)₂, CH₂CH₂CH₂N(CH₃)₂, CH₂CH₂CH₂N(Et)₂, CH(CH₃)CH₂OH, CH(CH₃)COOCH₃ or CH₂CH(OH)CH₂CH₃, or a pharmaceutically acceptable salt thereof.

5-6. (Cancelled)

7. (Currently amended) The compound according to claim 1, wherein R^4 is a group shown below, or a pharmaceutically acceptable salt thereof [Formula 2]

(wherein, Me is methyl; Ac is acetyl; Ms is methanesulfonyl).

- 8. (Cancelled)
- 9. (Previously presented) The compound according to claim 7, wherein R¹ is p-fluorobenzyl, or a pharmaceutically acceptable salt thereof.
- 10. (Previously presented) The compound according to claim 7, wherein R¹ is p-fluorobenzyl; R² is hydrogen; R³ is CH₂CH₂OCH₃, N(CH₃)₂, CH₂CH₂CN, CH₂CH₂N(CH₃)₂, CH₂CH₂CH₂N(CH₃)₂, or CH₂CH(OH)CH₂CH₃; or a pharmaceutically acceptable salt thereof.

11-21. (Cancelled)